Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Liquidia (LQDA) stock in plain English

Free brief · no signupStart here
LQDAPublished Nov 13, 2026
Liquidia Corp
Healthcare · Drug Manufacturers - Specialty & Generic
Manufactures inhaled dry powder formulations for patients suffering from rare pulmonary hypertension diseases.
Assets:
Morrisville facilityOperates manufacturing and laboratory operations in North Carolina.
PRINT platformPatented particle molding technology for precise dry powder drug delivery.
Yutrepia formulationDry powder inhaled formulation of treprostinil for pulmonary arterial hypertension.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

45
OPS ScoreOperating finances
Latest quote
+0.41%$56.63
$5.10B
n/a (loss)
$621.52M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was LQDA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Liquidia (LQDA) do?

Liquidia Corp (LQDA) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Manufactures inhaled dry powder formulations for patients suffering from rare pulmonary hypertension diseases. Engineers uniform dry powder drug particles to improve inhaled medicine delivery using precision molding technology. It is worth $5.10B on the market and sold $621.52M over the last year.

Market cap
$5.10B
P/E ratio
None (reported a loss)
Annual sales
$621.52M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 13, 2026

Brands and businesses behind LQDA

  • Yutrepia: This inhaled dry powder formulation delivers treprostinil to treat pulmonary arterial hypertension through prescription sales.

LQDA’s flags, in plain English

Each flag is a number from Liquidia’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Wide Gross Margin

Gross margin of 92.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 192.5% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Cheap on Cash Flow

Priced at 17.5 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Burning Cash

Losing money, profit margin of -15.2%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about LQDA

How big is Liquidia?

Liquidia’s market cap is $5.10B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $621.52M: what customers paid the company over the last year, before any costs.

What is LQDA’s P/E ratio?

LQDA has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with LQDA?

United Therapeutics actively pursues patent litigation to block commercial sales of the primary treprostinil product. That is one risk on Liquidia’s card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Liquidia’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. LQDA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card